×
About 82,620 results

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Oct 14th, 2022 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome. Ankylosing spondylitis (AS), the most common form of SpA, fr...

Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury
https://clinicaltrials.gov/ct2/show/NCT04136743

Oct 14th, 2022 - This is randomized controlled trial to determine the efficacy of autologous, micro-fragmented adipose tissue (MFAT) injection under ultrasound guidance for chronic, nonresponsive shoulder pain due to rotator cuff disease (i.e., rotator cuff tendinopathy) in persons with spinal cord injury (SCI). The control for this study, to which MFAT will be compared, is corticosteroid injection into the sub...

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
https://clinicaltrials.gov/ct2/show/NCT04032470

Oct 14th, 2022 - To compile characteristics of real-world outcomes using Deep Brain Stimulation (DBS) for the treatment of Essential Tremor to add to the evidence available for treatment of ET.

Acoustic Stimulation for Seizure Suppression
https://clinicaltrials.gov/ct2/show/NCT03198494

Oct 14th, 2022 - To test the feasibility of wearing an earphone system delivering acoustic stimulation during a night of sleep in adult epilepsy patients monitored in an inpatient unit. To determine the acute physiological effects of low-frequency acoustic stimulation on interictal epileptiform discharge (IED) frequency during NREM sleep in adult patients with epilepsy in an ambulatory setting. To determine the...

Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT03711448

Oct 14th, 2022 - Giant cell arteritis (GCA) is the most common form of vasculitis after age 50. It is a vasculitis affecting the large vessels, in particular the aorta and its collateral vessels, especially those in the external carotid area. Corticosteroids are the cornerstone of GCA treatment. They are very effective but are generally continued for 18 to 24 months or more since at least 30% of patients with G...

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
https://clinicaltrials.gov/ct2/show/NCT03733067

Oct 14th, 2022 - Pr(SqrRoot)(Copyright)cis Rare heterozygous mutations in cytotoxic T-lymphocyte antigen-4 (CTLA4) lead to a monogenetic defect that presents with a heterogeneous clinical phenotype of recurrent infections, lymphoproliferation, autoimmunity, and lymphocytic infiltration of target organs. Management is challenging and focuses on treating infections, autoimmune complications, and end organ damage ...

Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan
https://clinicaltrials.gov/ct2/show/NCT00341874

Oct 14th, 2022 - Objective: One objective of this study is to genetically map and identify mutated genes for human hereditary hearing loss. A second objective is to study the function of these genes in the auditory system using mouse models. Human hereditary hearing impairment is the result of abnormal ear development, abnormal ear function or both. Although the genes for numerous deafness loci have been mapped...

Feasibility of Stimulating the Visual Cortex in Blind
https://clinicaltrials.gov/ct2/show/NCT02747589

Oct 14th, 2022 - In this study, the investigators intend to evaluate the use of a commercially available neurostimulator system, NeuroPace RNS System to stimulate the visual cortex. The NeuroPace RNS System has a proven record of safety and reliability was approved by the FDA in November 2013. The RNS System is indicated for use in patients with epilepsy and includes a skull implanted neurostimulator. No modifi...

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
https://clinicaltrials.gov/ct2/show/NCT00254462

Oct 14th, 2022 - Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders in children. Children with ADHD often have impaired functioning in home and school and usually experience difficulty relating to peers. If left untreated, the disorder can have long-term adverse effects into adolescence and adulthood. Atomoxetine is a selective noradrenergic reuptake inhibitor that is FDA...

Genetic, Brain Structure, and Environmental Effects on ADHD
https://clinicaltrials.gov/ct2/show/NCT01721720

Oct 14th, 2022 - OBJECTIVES: This study aims to provide novel phenotypes for genomic studies into Attention- Deficit Hyperactivity Disorder (ADHD), one of the most common and heritable of all neuropsychiatric disorders. It proposes to split the disorder into neurobiologically more meaningful entities by delineating subgroups based on neurobehavioral profiles. It will also explore factors that impact clinical co...

Natural History Study of Children and Adults With Medullary Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT01660984

Oct 14th, 2022 - Background: Medullary Thyroid Carcinoma (MTC) is a calcitonin producing tumor arising from the parafollicular C cells of thyroid. In children and adults, MTC is usually seen in association with Multiple Endocrine Neoplasia (MEN) 2A and 2B, which are rare cancer syndromes resulting from germline mutations of Rearranged during Transfection (RET) proto-oncogene. MTC develops in virtually all patie...

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
https://clinicaltrials.gov/ct2/show/NCT00271622

Oct 14th, 2022 - The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders. The evaluations may be used to determine if the participant meets criteria for participation in specific research protocols at the National Institute of Mental Health (NIMH) and other collaborativ...

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04490109

Oct 14th, 2022 - This is a Prospective, Vehicle Controlled, Double-Blind, Multicenter, Randomized Phase II Trial, comparing the effect of twice daily B244 applications for 4 weeks vs vehicle applications on treatment of mild to moderate pruritus associated with atopic dermatitis. Approximately 576 subjects may be enrolled. The total duration of the study will be approximately 11 weeks. Participants will report ...

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)
https://clinicaltrials.gov/ct2/show/NCT03895658

Oct 14th, 2022 - Despite advances in antidepressant interventions, none has replaced electroconvulsive therapy (ECT) in its acute efficacy and spectrum of action in severely depressed patients, including in psychotic depression, catatonia, and acutely suicidal patients. However, ECT carries a risk of significant adverse effects including cognitive and physiological side effects, some of which can be long term. ...

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
https://clinicaltrials.gov/ct2/show/NCT04752774

Oct 14th, 2022 - The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
https://clinicaltrials.gov/ct2/show/NCT04750928

Oct 14th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic tumor predisposition syndrome (incidence of 1:3000), which results in the development of progressive tumor and non-tumor manifestations, the majority of which have no effective medical therapies. 25-50% of individuals with neurofibromatosis type 1 (NF1) develop histologically benign plexiform neurofibromas (PN), which can cause substantial...

Natural History Study of Patients With Neurofibromatosis Type I
https://clinicaltrials.gov/ct2/show/NCT00924196

Oct 14th, 2022 - Background Neurofibromatosis Type 1 (NF1) is an autosomal dominant, progressive genetic disorder characterized by diverse clinical manifestations. Patients with NF1 have an increased risk of developing tumors of the central and peripheral nervous system including plexiform neurofibromas (PN), dermal neurofibromas, optic pathway tumors, brain tumors, malignant peripheral nerve sheath tumors (MPN...

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

Oct 14th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patients with standard-risk average (SR-Avg) B-ALL who are negative for minimal residual disease (MRD) by flow cytometry but have detectable or indetermina...

Deep Brain Stimulation Surgery for Movement Disorders
https://clinicaltrials.gov/ct2/show/NCT01581580

Oct 14th, 2022 - Objective: The objective of this protocol is to provide standard of care DBS surgery and to collect prospective physiology data related to DBS therapy and motor and cognitive function in people with medically refractory Parkinson s disease (PD), dystonia, and essential tremor (ET). All treatment under this protocol will be based on the current standard of care for DBS surgery. Study Population:...

Post-market Assessment of Biodesign Dural Repair Grafts
https://clinicaltrials.gov/ct2/show/NCT04057157

Oct 14th, 2022 - The purpose of this clinical study is to gather post-market clinical evidence on the use of the Biodesign® Dural and Duraplasty Grafts when used as a dura substitute of the dura mater.